Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,470
datasets available to search
ShareScore release 0.9.0
Dataset results
2,470 results for “Acute myeloid leukemia”
RNA-seq of bone marrow samples from acute myeloid leukemia patients and healthy individuals
Open the record for dataset details and reuse information.
Hematopathologist-annotated mass cytometry dataset of acute myeloid leukemia diagnostic specimens
Open the record for dataset details and reuse information.
RNA-seq data from TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia
<p class="BDAbstract"><span><span><span><span><span><span><span><span><span><span><span>TAS4464, a potent, selective small molecule NEDD8-activating enzyme (NAE) inhibitor, leads to inactivation of cullin-RING E3 ubiquitin ligases (CRLs) and consequent accumulations of its substrate proteins. Here, we investigated the antitumor properties and action mechanism of TAS4464 in acute myeloid leukemia (AML). TAS4464 induced apoptotic cell death in various AML cell lines. TAS4464 treatments resulted in the activation of both the caspase-9-mediated in intrinsic apoptotic pathway and caspase-8-mediated extrinsic apoptotic pathway in AML cells; combined treatment with inhibitors of these caspases markedly diminished TAS4464 induced apoptosis. In each apoptotic pathway, TAS4464 induced the mRNA transcription of the intrinsic proapoptotic factor NOXA and decreased that of the extrinsic antiapoptotic factor c-FLIP. RNA-sequencing analysis showed that the signaling pathway of the CRL substrate c-Myc was enriched after TAS4464 treatment. Chromatin immunoprecipitation (ChIP) assay revealed that TAS4464 induced c-Myc bound to the <i>PMAIP1</i> (encoding NOXA) and <i>CFLAR</i> (encoding c-FLIP) promoter regions, and siRNA-mediated c-Myc knockdown neutralized both TAS4464-mediated NOXA induction and c-FLIP downregulation. TAS4464 activated both caspase-8 and caspase-9 along with an increase in NOXA and a decrease in c-FLIP, resulting in complete tumor remission in a human AML xenograft model. These findings suggest that NAE inhibition leads to anti-AML activity via a novel c-Myc-dependent apoptosis induction mechanism.</span></span></span></span></span></span></span></span></span></span></span></p>
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
ClinicalTrials.gov study NCT01465386. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02249091. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02003573. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
ClinicalTrials.gov study NCT02337478. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT04905407. IPD Sharing: NO. Countries: 2. Publications: 0.
A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
ClinicalTrials.gov study NCT04625413. IPD Sharing: YES. Countries: 1. Publications: 0.
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT00778375. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Ei
ClinicalTrials.gov study NCT00045942. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
ClinicalTrials.gov study NCT01894477. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
ClinicalTrials.gov study NCT03451084. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
ClinicalTrials.gov study NCT03844997. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic S
ClinicalTrials.gov study NCT04802161. IPD Sharing: YES. Countries: 1. Publications: 0.
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov study NCT05703542. IPD Sharing: YES. Countries: 1. Publications: 0.
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
ClinicalTrials.gov study NCT00480987. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients
ClinicalTrials.gov study NCT04259372. IPD Sharing: NO. Countries: 0. Publications: 3.
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
ClinicalTrials.gov study NCT00718159. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
ClinicalTrials.gov study NCT00818649. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.